BioRestorative Therapies develops regenerative medicine products using cell and tissue protocols, primarily involving adult stem cells. News about BRTX centers on BRTX-100, its autologous hypoxic-cultured mesenchymal stem cell therapy for chronic lumbar disc disease, including clinical trial updates, safety and efficacy data presentations, and regulatory interactions tied to the program.
The company also reports developments involving its ThermoStem metabolic program and its commercial BioCosmeceutical platform. Recurring updates include scientific conference presentations, collaborations supporting BioCosmeceutical commercialization, capital actions, shareholder communications, and business updates related to development spending and platform expansion.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BioRestorative Therapies, Inc. (BRTX), a clinical-stage company focused on stem cell therapies, has completed enrollment for the safety run-in of its Phase 2 clinical study of BRTX-100. This innovative treatment aims to address chronic lumbar disc disease (cLDD) by targeting areas with low blood flow. The study is randomized and double-blinded, involving up to 99 patients at 15 U.S. clinical sites. CEO Lance Alstodt highlighted the milestone, stating that positive safety results would enable broader enrollment and further development of BRTX-100 across other medical applications. The company aims to leverage this platform for expedited regulatory pathways. Initial clinical data is expected to be released in the second half of 2023.